1. Medicines
  2. Rheumatology
  3. COSENTYX® (secukinumab)
  4. Dosing and product information

Prescribing information

 

Dosing and product information

   

See the Cosentyx dosing schedule and summary of product characteristics.

PsA, AS and nr-axSpA dosing: give your Cosentyx patients the ease of a monthly maintenance schedule1

Cosentyx, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

A table showing that psoriatic arthritis patients are initially assigned to one of three treatment regimens: First-line biologic with mild or no psoriasis, who receive 150 mg; First-line biologic with moderate to severe plaque psoriasis who receive 300 mg; and anti-TNF inadequate reponders, who receive 300 mg.

*PsA patients initiated on 150 mg can be increased to 300 mg based on clinical response.

Dosing table. The recommended dose for psoriatic arthritis is either 150 mg or 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.

Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

For patients with active AS, the recommended dose is 150 mg by subcutaneous injection. AS patients initiated on 150 mg can be increased to 300 mg based on clinical response.

Dosing table. The recommended dose for ankylosing spondylitis is 150mg with initial dosing at Weeks 0,1,2,3, and 4, followed by monthly maintenance dosing. Dose can be increased to 300mg based on clinical response.

Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

For patients with active nr-axSpA, the recommended dose is 150 mg by subcutaneous injection. 

 

Supporting your Cosentyx patients virtually

We have now digitised our patient packs, leaflets, dosing charts and more. Make sure you can continue to support your Cosentyx patients virtually by exploring our patient resources.

Show more

More product information

Summary of product characteristics for Cosentyx

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; SC, subcutaneous; TNF, tumour necrosis factor.

Reference

  1. Cosentyx Summary of Product Characteristics.
UK | April 2021 | 108786
Rheumatology
Article
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]